Zojwalla Naseem's Form 4 filing
Olema Pharmaceuticals, Inc. (OLMA) · filed Dec 11, 2024
- Accession no.
- 0001415889-24-029026
- Filed
- Dec 11, 2024
- Trade date
- Dec 9-11, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market sales total $250.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Zojwalla NaseemCIK 0001905871 | Officer (CHIEF MEDICAL OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 9, 2024 | Common Stock | AGrant or awardAcquired | +52,000 | $0.00 | $0 | 143,314 | Direct | |
| Dec 10, 2024 | Common Stock | SSaleDisposed | −13,283 | $9.37 | −$124,461.71 | 130,031 | Direct | |
| Dec 11, 2024 | Common Stock | SSaleDisposed | −14,202 | $8.66 | −$122,989.32 | 115,829 | Direct | |
| Dec 11, 2024 | Common Stock | SSaleDisposed | −320 | $9.39 | −$3,004.8 | 115,509 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.